Abstract
Objectives:
To determine the incidence and risk factors for thromboembolic events (TE) and febrile neutropenia (FN) in patients receiving systemic chemotherapy for early breast cancer (EBC).
Methods:
325 patients received FEC75, FEC100-T or ECaP for EBC in 2013.
Results:
TE occurred in 7.4% and FN in 19.1% of patients. Risk factors for TE were: central venous catheter (p = 0.011). Risk factors for FN were: FEC100-T treatment versus FEC75 and ECaP (p ≤ 0.001); lower pre-treatment neutrophil count (p = 0.009) and poorer performance status (p = 0.012). Two patients died from treatment-related toxicities.
Conclusion:
In real-world experience, the majority of patients completed adequate treatment, despite significant complications.
Keywords:
Adjuvant chemotherapy; Early breast cancer (EBC); Febrile neutropenia; Neoadjuvant chemotherapy; Thromboembolic events; Treatment related toxicity.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acute Coronary Syndrome / epidemiology*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / pathology
-
Carcinoma, Lobular / drug therapy*
-
Carcinoma, Lobular / pathology
-
Chemotherapy, Adjuvant / adverse effects
-
Chemotherapy-Induced Febrile Neutropenia / epidemiology*
-
Cyclophosphamide / administration & dosage
-
Docetaxel
-
Dose-Response Relationship, Drug
-
Epirubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Incidence
-
Mastectomy
-
Mastectomy, Segmental
-
Middle Aged
-
Neoadjuvant Therapy / adverse effects
-
Neoplasm Staging
-
Paclitaxel / administration & dosage
-
Pulmonary Embolism / epidemiology*
-
Retrospective Studies
-
Risk Factors
-
Sentinel Lymph Node Biopsy
-
Stroke / epidemiology*
-
Taxoids / administration & dosage
-
Thromboembolism / epidemiology
-
Venous Thrombosis / epidemiology*
Substances
-
Taxoids
-
Docetaxel
-
Epirubicin
-
Cyclophosphamide
-
Paclitaxel
-
Fluorouracil